Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Turning Point Therapeutics, Inc. - Common stock (NQ: TPTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 16, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 75.98 (9)
Ask (Size) 76.00 (7)
Prev. Close 76.01
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 50,074,277
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics
From Bristol Myers Squibb
Via Business Wire
Blue Chip Stocks In Focus: Bristol-Myers Squibb
The company has grown earnings by more than 20% per year on average over the last five and ten years. This explosive growth has enabled the company to continue growing its dividend. 
Via Talk Markets

Performance

More News

Read More
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Analyst Ratings for Turning Point
Via Benzinga
Turning Point Secures Positive FDA Feedback For Planned Lung Cancer Drug Submission
Via Benzinga
The 3 Best Market Sectors for the Second Half of 2022
Via InvestorPlace
TPTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Turning Point Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTX
From Kahn Swick & Foti, LLC
Via Business Wire
UnitedHealth, Shockwave Lead 5 Healthy Stocks Breaking Out Or Setting Up
Via Investor's Business Daily
INVESTIGATION ALERT: Halper Sadeh LLP Investigates VMW, TPTX, CTT, CTEK
From Halper Sadeh LLP
Via AccessWire
10 Biggest Price Target Changes For Monday
Via Benzinga
TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTX
From Kahn Swick & Foti, LLC
Via Business Wire
69 Biggest Movers From Friday
Via Benzinga
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
Via Benzinga
The Acquisition of Turning Point Therapeutics By BMY- Bristol- Myers.
Via Best Stocks
Mid-Afternoon Market Update: Gold Drops 1%; Sprague Resources Shares Spike Higher
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Mid-Day Market Update: Nasdaq Down 300 Points; Turning Point Therapeutics Shares Jump
Via Benzinga
40 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
TPTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Turning Point Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
CrowdStrike (CRWD) Stock Dips Despite Earnings Beat
Via InvestorPlace
TPTX Stock Soars 115% as Bristol Myers Announces Takeover of Turning Point Therapeutics
Via InvestorPlace
Mid-Morning Market Update: Markets Open Lower; US Economy Adds 390,000 Jobs In May
Via Benzinga
Bristol Myers Snaps Up Turning Point For $4.1 Billion In Cash — Is The Biotech Bear Dead?
Via Investor's Business Daily
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.